小核仁RNAs及其衍生RNAs的研究进展

小核仁RNAs(small nucleolarRNAs,snoRNAs)是一类发现较早且位于核仁内的小非编码RNAs,在核糖体RNAs(ribosomalRNAs,rRNAs)、信使RNAs(messengerRNAs,mRNAs)、小核RNAs(small nuclearRNAs,snRNAs)的成熟及修饰中均发挥重要作用。snoRNAs的功能及其作用途径一直以来均是学术界的研究热点。目前,snoRNAs对rRNAs的化学修饰作用已得到广泛认可。另外,有研究表明snoRNAs与一些遗传疾病以及肿瘤性疾病的发生发展存在密切关联。近年来研究发现,部分snoRNAs经切割可生成更小的、有功能的RNAs,即小核仁RNAs衍生RNAs(snoRNAs derivedRNAs,sdRNAs),这些sdRNAs中部分具有微小RNAs(microRNAs,miRNAs)的特征,可发挥类似miRNA的作用,这一发现极大地拓展了snoRNAs的作用机制方式。结合国内外研究现状,在总结snoRNAs的结构和基本功能的基础上对sdRNAs与miRNAs之间的相关性进行了综述,以期为后续的相关研究提供参考。     

内源小RNAs在植物病原体抗性反应中的作用

内源小RNAs是动植物基因表达的重要调节分子,它们可以通过指导mRNA的降解、抑制翻译或染色体修饰等机制,在转录水平或转录后水平或两个水平沉默基因.内源小RNAs在植物生长发育和生物和非生物胁迫适应反应中具有重要作用,其中3种内源性的小RNAs参与了植物基本免疫反应和对病原体的特异性免疫反应.内源小RNAs的发现为植物抗菌和抗病研究开辟了新思路,就这几种内源性的小RNAs的产生和它们在植物抗病原体反应中的作用做一概述.     

内源小RNAs在植物胁迫反应中的作用

世界范围内, 农作物的产量都容易受到各种生物和非生物因素的影响, 对植物逆境适应性反应机制的深入研究有助于我们采取新的措施, 以提高作物的逆境适应性。以前通常认为植物适应逆境胁迫的机制主要涉及相关基因在转录水平的调节, 然而, 近来发现部分内源小RNAs(siRNAs), 如miRNAs、 nat-siRNAs和 lsiRNAs不仅可以调节植物的生长发育,而且在植物逆境反应中具有重要作用。文章就这些内源小RNAs在氧、矿质元素、干旱、低温、脱落酸、机械、重金属、生物及其他环境因素胁迫中的作用机制做一概述。     

植物小RNAs的研究进展

小RNAs(长度小于40 nt)是nc-RNAs重要的一部分,现在植物中已发现了多种小RNAs,如小干扰RNAs(siRNAs)、微小RNAs(miRNAs)、反式作用的小干扰RNAs、天然反义转录小干扰RNAs、异染色质小干扰RNAs、长小片段小干扰RNAs、天然反义转录的微小RNAs及其一些未命名的小RNAs.成熟的小RNAs聚集相关的蛋白质因子,可以抑制转录,导致转录水平的基因沉默(TGS);或介导目标mRNA的剪切,抑制翻译,导致转录后水平基因沉默(PTGS).就这些植物小RNAs产生及其作用的研究进展作一概述     

小RNAs作用机制的研究进展

RNAi的发现引发了生物学的一次革命, 也揭示了一种原来未被发现的, 通过小RNAs(大小~20–30 nt)家族在转录水平或转录后水平调解基因表达的方式。在真核生物中, 这些小RNAs包括siRNAs、miRNAs、piRNAs、scnRNAs、21U-RNAs和其他一些小RNAs等。它们通过调节基因表达来控制细胞的代谢、生长和分化, 维持基因组的完整性, 协调生殖细胞的成熟和抑制病毒对细胞的侵袭以及转座成分的转座。文章综述了这些小RNAs在鉴定和生物合成方面的研究进展, 并讨论了它们对基因表达的调节作用。     

小RNAs在沉默转座因子中的作用

在很多生物基因组中都存在DNA成分的转座序列,它们能够转座到基因组的很多位点,对基因组造成很大的危害,如破坏编码基因、改变基因表达的调节网络、使染色体断裂或造成大范围基因重排等。真核生物已经进化出了多种机制来控制这些寄生核酸序列造成的损伤,以维持基因组完整性。虽然这些机制在不同生物中有些差异,但其中一种主要的机制是通过小RNAs介导的,这些小RNAs包括小干扰RNAs、piwi相互作用的小RNAs、微小RNAs、扫描RNAs和21U-RNAs等。这些小RNAs可以通过DNA水平剪切转座序列,或在转录和(或)转录后水平沉默转座成分。该文就这些小RNAs沉默转座成分的机制和功能做一论述。     

小RNAs在生殖细胞发育过程中的作用

很多动物可以产生具调节作用的小RNAs,根据产生方式和作用机制可以将它们分为三类:微小RNAs(miRNAs)、与Piwi相互作用的RNAs(piRNAs)和内源小干扰RNAs(endo-siRNAs),这些小RNAs可以在生物生殖细胞发育过程中发挥重要作用。其中miRNAs的主要作用是调节蛋白质基因的表达;piRNAs主要的作用是沉默转座因子,但piRNAs主要存在于生殖细胞中;endo-siRNAs则可能具有上述两种主要作用。该文论述了这三种小RNAs在生物生殖细胞发育过程中的作用,同时也讨论了它们在治疗生物不育及其在生物节育方面的应用前景。     

增殖相关信号通路在肝癌中的研究进展

肝癌是世界范围内最常见的恶性肿瘤之一.随着分子生物学技术的迅速发展,阐明肝癌的分子机制以及发现新的治疗靶点,是当今肝癌领域的研究热点之一.目前,已发现肝癌的发病与细胞内增殖信号通路有关,比如Wnt/β-Catenin、PI3K/AKT、JAK/STAT、Hedgehog、Hippo等.本文介绍了细胞增殖与肝癌的关系、肝...     

干细胞及微小RNAs治疗肺纤维化的研究进展

肺纤维化是一种严重危害人类健康的呼吸系统常见并发症,是各种不同病因的肺间质疾病的最后共同结果。其严重影响人体呼吸功能,且随着病情和肺部损伤的加重,患者呼吸功能不断恶化,其发病率和死亡率逐年增加。干细胞作为一种具有自我复制能力的多潜能细胞,近年研究发现其与微小RNAs在治疗肺部疾病中均具有重要作用,了解干细胞及微小RNAs与肺纤维化治疗之间的关系具有重要意义。本文将主要介绍几种干细胞及微小RNAs治疗肺纤维化的相关作用机制,此综述结果将为预防和治疗肺纤维化提供新的研究方向。     

GP73及其相关miRNA在肝癌中的研究进展

高尔基体蛋白73 (Golgi protein 73, GP73)是位于顺式高尔基体膜上的糖基化跨膜蛋白,其在肿瘤的发展进程中具有重要作用,是肿瘤治疗的潜在靶标。目前研究表明, GP73可作为辅助诊断肝细胞癌(hepatocellular carcinoma, HCC)的血清学标志物。随着GP73的深入研究,与GP73有关的微RNA (microRNA, mi RNA)也逐渐被挖掘出来。GP73相关mi RNA与多种肿瘤的发生、发展密切相关,其中mi R-212、mi R-27a等mi RNA能抑制HCC的侵袭及转移, GP73与mi R-27b、mi R-493-5p等能作为HCC患者预后的生物标志物。因此, GP73相关mi RNA用于肝癌的诊治是有前景的。本文总结了GP73及其相关mi RNA在肝癌发展中的作用以及机制,希望为肝癌的机制研究和诊疗提供思路。     

Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion

CC chemokine receptor 1 (CCR1) has an important role in the recruitment of leukocytes to the site of inflammation. The migration and metastasis of tumor cells shares many similarities with leukocyte trafficking, which is mainly regulated by chemokine receptor-ligand interactions. CCR1 is highly expressed in hepatocellular carcinoma (HCC) cells and tissues with unknown functions. In this study, we silenced CCR1 expression in the human HCC cell line HCCLM3 using artificial microRNA (miRNA)-mediated RNA interference (RNAi) and examined the invasiveness and proliferation of CCR1-silenced HCCLM3 cells and the matrix metalloproteinase (MMP) activity. The miRNA-mediated knockdown expression of CCR1 significantly inhibited the invasive ability of HCCLM3 cells, but had only a minor effect on the cellular proliferation rate. Moreover, CCR1 knockdown significantly reduced the secretion of MMP-2. Together, these findings indicate that CCR1 has an important role in HCCLM3 invasion and that CCR1 might be a new target of HCC treatment.     

Anti-proliferative and pro-apoptotic effect of carvacrol on human hepatocellular carcinoma cell line HepG-2

Carvacrol is one of the members of monoterpene phenol and is present in the volatile oils of Thymus vulgaris, Carum copticum, origanum and oregano. It is a safe food additive commonly used in our daily life, and few studies have indicated that carvacrol has anti-hepatocarcinogenic activities. The rationale of the study was to examine whether carvacrol affects apoptosis of human hepatoma HepG2 cells. In this study, we showed that carvacrol inhibited HepG2 cell growth by inducing apoptosis as evidenced by Hoechst 33258 stain and Flow cytometric (FCM) analysis. Incubation of HepG2 cells with carvacrol for 24 h induced apoptosis by the activation of caspase-3, cleavage of PARP and decreased Bcl-2 gene expression. These results demonstrated that a significant fraction of carvacrol treated cells died by an apoptotic pathway in HepG2 cells. Moreover, carvacrol selectively altered the phosphorylation state of members of the MAPK superfamily, decreasing phosphorylation of ERK1/2 significantly in a dose-dependent manner, and activated phosphorylation of p38 but not affecting JNK MAPK phosphorylation. These results suggest that carvacrol may induce apoptosis by direct activation of the mitochondrial pathway, and the mitogen-activated protein kinase pathway may play an important role in the antitumor effect of carvacrol. These results have identified, for the first time, the biological activity of carvacrol in HepG2 cells and should lead to further development of carvacrol for liver disease therapy.     

Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma

Background

Kinase inhibitor sorafenib is the most widely used drug for advanced HCC clinical treatment nowadays. However, sorafenib administration is only effective for a small portion of HCC patients, and the majority develop sorafenib-resistance during treatment. Thus, it is urgent to discover the endogenous mechanism and identify new pharmaceutical targets of sorafenib-resistance.

TRAIL联合顺铂对小鼠移植型肝癌抑制作用及机制研究

目的探讨肿瘤坏死因子相关的凋亡诱导配体(tumor necrosis factor-related apoptosis inducing ligand,TRAIL)联合顺铂(cisplatin,DDP)对小鼠移植型肝癌的抑制作用及机制。方法将H22小鼠移植型肝癌模型随机分为生理盐水组、TRAIL组、TRAIL+DDP组和DDP组,称取瘤重并分析抑瘤率,Hoechst 33342荧光染色法检测细胞凋亡,免疫组织化学染色检测Caspase-3表达。结果与生理盐水组比较,TRAIL、DDP对小鼠移植型肝癌生长具有明显的抑制作用(P<0.05);TRAIL与DDP联合用药具有增效作用(P<0.05),可明显提高肝癌细胞的凋亡率(P<0.05)、上调Caspase-3表达(P<0.01)。结论 TRAIL与DDP联合用药对小鼠移植型肝癌生长具有协同抑制作用,其机制可能与其协同促进Caspase-3的表达有关。     

Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma

Background

Despite the recent identification of several prognostic gene signatures, the lack of common genes among experimental cohorts has posed a considerable challenge in uncovering the molecular basis underlying hepatocellular carcinoma (HCC) recurrence for application in clinical purposes. To overcome the limitations of individual gene-based analysis, we applied a pathway-based approach for analysis of HCC recurrence.

Results

By implementing a permutation-based semi-supervised principal component analysis algorithm using the optimal principal component, we selected sixty-four pathways associated with hepatitis B virus (HBV)-positive HCC recurrence (p < 0.01), from our microarray dataset composed of 142 HBV-positive HCCs. In relation to the public HBV- and public hepatitis C virus (HCV)-positive HCC datasets, we detected 46 (71.9%) and 18 (28.1%) common recurrence-associated pathways, respectively. However, overlap of recurrence-associated genes between datasets was rare, further supporting the utility of the pathway-based approach for recurrence analysis between different HCC datasets. Non-supervised clustering of the 64 recurrence-associated pathways facilitated the classification of HCC patients into high- and low-risk subgroups, based on risk of recurrence (p < 0.0001). The pathways identified were additionally successfully applied to discriminate subgroups depending on recurrence risk within the public HCC datasets. Through multivariate analysis, these recurrence-associated pathways were identified as an independent prognostic factor (p < 0.0001) along with tumor number, tumor size and Edmondson’s grade. Moreover, the pathway-based approach had a clinical advantage in terms of discriminating the high-risk subgroup (N = 12) among patients (N = 26) with small HCC (<3 cm).

Conclusions

Using pathway-based analysis, we successfully identified the pathways involved in recurrence of HBV-positive HCC that may be effectively used as prognostic markers.

Electronic supplementary material

The online version of this article (doi:10.1186/s12864-015-1472-x) contains supplementary material, which is available to authorized users.     

Rho GTPases in hepatocellular carcinoma

Rho GTPases are major regulators of signal transduction pathways and play key roles in processes including actin dynamics, cell cycle progression, cell survival and gene expression, whose deregulation may lead to tumorigenesis. A growing number of in vitro and in vivo studies using tumor-derived cell lines, primary tumors and animal cancer models strongly suggest that altered Rho GTPase signaling plays an important role in the initiation as well as in the progression of hepatocellular carcinoma (HCC), one of the deadliest human cancers in the world. These alterations can occur at the level of the GTPases themselves or of one of their regulators or effectors. The participation into the tumorigenic process can occur either through the over-expression of one of these components which presents an oncogenic activity as illustrated with RhoA and C or through the attenuation of the expression of a component presenting tumor suppressor activity as for Cdc42 or the RhoGAP, DLC-1. Consequently, these observations reflect the heterogeneity and the complexity of liver carcinogenesis. Recently, pharmacological approaches targeting Rho GTPase signaling have been used in HCC-derived models with relative success but remain to be validated in more physiologically relevant systems. Therefore, therapeutic approaches targeting Rho GTPase signaling may provide a novel alternative for anti-HCC therapy.     

Overexpression of RhoGDI,a novel predictor of distant metastasis,promotes cell proliferation and migration in hepatocellular carcinoma

RhoGDI (Rho GDP-dissociation inhibitor alpha, or RhoGDIα) was identified as a regulator of Rho GTPases, but its role in cancer remains controversial. In this study, increased expression of RhoGDI was detected in hepatocellular carcinoma (HCC) cell lines and tissues with highly metastatic potential. RhoGDI overexpression correlated with postoperative distant metastasis. Enforced expression of RhoGDI in HCC cells significantly enhanced cell proliferation and migration. Conversely, knockdown of RhoGDI caused an inhibition of the aggressive phenotypes of HCC cells. Furthermore, RhoGDI up-regulated Rho, but not Rac, and enhanced PI3K/AKT and MAPK pathway activity. Our findings suggest that RhoGDI overexpression is a predictor of distant metastasis and plays an important role in the progression of HCC.     

New mutations of Nogo-C in hepatocellular carcinoma

The neurite outgrowth inhibitor Nogo has attracted great interest, but its relevance with hepatocellular carcinoma has not been reported. This paper first found mutations of Nogo-C in HCC patients from Qidong in China: A172G (Thr58Ala), A340G (Arg114Gly), A571G (Ile191Val). In six examined patient cases from Qidong, the mutations occurred in five cases. The mutation Arg114Gly was predicted bioinformatically to affect Nogo-66 dimensional structure of Nogo-C. Our previous works also had indicated that mutant Nogo-C promoted liver cancer cell line apoptosis and resulted in molecular marker of HCC p53 gene transfer from nucleus to cytoplast. Above results revealed a new physiological role and clinical implications of Nogo-C on HCC.     

Bioluminescent imaging of hepatocellular carcinoma in live mice

A non-invasive orthotopic hepatocellular carcinoma (HCC) model was created with human HCC cells (HepG-Luc) constitutively expressing luciferase (Luc) in nude mice. Development of tumor growth and response to anti-tumor therapy combined with 5-fluorouracil and cisplatin was monitored by whole-body bioluminescent imaging (BLI). Luciferase activity in the tumor, determined by BLI, correlated with the tumor volume and weight. The anti-tumor therapy proved effective by BLI monitoring. In conclusion, BLI by luciferase provides a non-invasive method of monitoring tumor activities that can prove useful for therapeutic intervention studies.     

microRNAs: Key players in virus-associated hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is known as one of the major health problems worldwide. Pathological analysis indicated that a variety of risk factors including genetical (i.e., alteration of tumor suppressors and oncogenes) and environmental factors (i.e., viruses) are involved in beginning and development of HCC. The understanding of these risk factors could guide scientists and clinicians to design effective therapeutic options in HCC treatment. Various viruses such as hepatitis B virus (HBV) and hepatitis C virus (HCV) via targeting several cellular and molecular pathways involved in HCC pathogenesis. Among various cellular and molecular targets, microRNAs (miRNAs) have appeared as key players in HCC progression. miRNAs are short noncoding RNAs which could play important roles as oncogenes or tumor suppressors in several malignancies such as HCC. Deregulation of many miRNAs (i.e., miR-222, miR-25, miR-92a, miR-1, let-7f, and miR-21) could be associated with different stages of HCC. Besides miRNAs, exosomes are other particles which are involved in HCC pathogenesis via targeting different cargos, such as DNAs, RNAs, miRNAs, and proteins. In this review, we summarize the current knowledge of the role of miRNAs and exosomes as important players in HCC pathogenesis. Moreover, we highlighted HCV- and HBV-related miRNAs which led to HCC progression.